Regional EuroTimes
Date Posted 29/09/2009
Bausch & Lomb subsidiaries and CROMA will co-promote bromfenac in Europe
Bausch & Lomb have announced that several of its pharmaceutical subsidiaries have been granted rights from CROMA Pharma GmbH to co-promote and sell bromfenac ophthalmic solution in Europe when it becomes available to the market.
Bromfenac, a non-steroidal anti-inflammatory drug (NSAID), is designed for the treatment of postoperative ocular inflammation and pain following cataract extraction.
Bausch & Lomb say bromfenac has demonstrated both efficacy and safety in pivotal Phase III trials and it is expected to be the first ocular NSAID in Europe approved for twice-daily dosing.
CROMA has submitted bromfenac to the European Medicines Agency (EMEA) for centralised approval throughout the European Union.
Bromfenac is already approved in the US and Japan, where it is marketed by other companies.
“We are enthusiastic about the collaboration with CROMA, as we look forward to making bromfenac available in a large number of markets to support the unmet needs of patients and physicians alike,” said Charl van Zyl, vice-president, Pharmaceuticals, Europe, Middle East and Africa Region, Bausch & Lomb.
“The addition of bromfenac to the European portfolio strengthens our customer offering and further invigorates our anti-inflammatory business by providing access to a new pan-European prescription brand,” he said.
eTIMES newsletter
eTIMES is a new bi-monthly newsletter with the latest breaking news from the ESCRS and the world of ophthalmology.
eTIMES is a new bi-monthly newsletter with the latest breaking news from the ESCRS and the world of ophthalmology.
Media Guide 2010
Results from our readership survey plus information about advertising in EuroTimes
Results from our readership survey plus information about advertising in EuroTimes
Podcasts
Eye Contact features interviews with key opinion leaders in the world of ophthalmology
Eye Contact features interviews with key opinion leaders in the world of ophthalmology
Tuesday, 07 September 2010
www.eurotimes.org
EuroTimes Breaking News
Faster lasers and better lens surgery are improving options for higher myopes
Date Posted 07/09/2010 MORE HERE...
All-laser LASIK with Ziemer LDV femtosecond and Allegretto Wave Eye-Q provides highly satisfactory visual outcomes
Date Posted 07/09/2010 MORE HERE...
Removing epithelium with laser speeds healing and reduces pain of corneal surface ablation
Date Posted 07/09/2010 MORE HERE...
Ridley Lecture looks at life and death on the posterior capsule
Date Posted 06/09/2010 MORE HERE...
Evidence-based data a top priority for ESCRS
Date Posted 05/09/2010 MORE HERE...
New technology for measuring cornea biomechanics
Date Posted 05/09/2010 MORE HERE...
Industry Breaking News
Rayner launches small-incision IOL injector system
Date Posted 16/08/2010 MORE HERE...
OptiMedica sells retina and glaucoma business to Topcon
Date Posted 16/08/2010 MORE HERE...
Carl Zeiss Meditec announces 20 per cent increase in third quarter revenue
Date Posted 16/08/2010 MORE HERE...
New languages to select from on the Megatron® S4
Date Posted 16/08/2010 MORE HERE...